Patheon Agreement Sample Clauses
The Patheon Agreement clause defines the contractual relationship and terms between a client and Patheon, a company that provides pharmaceutical manufacturing and related services. This clause typically outlines the scope of services, responsibilities of each party, and key operational details such as timelines, quality standards, and payment terms. By clearly establishing the framework for collaboration, the clause ensures both parties understand their obligations and helps prevent disputes by providing a reference point for performance and expectations.
Patheon Agreement. S2 has provided to Santarus true, complete and correct copies of the Patheon Agreement and those certain Capital Expenditure and Equipment Agreement, dated as of May 26, 2010, between S2 and Patheon, and Quality Agreement, dated as of May 26, 2010, between S2 and Patheon, each as amended from time to time (collectively, the “Supplemental Patheon Agreements”). The Patheon Agreement and the Supplemental Patheon Agreements are the only agreements existing as of the Effective Date by which S2 has contracted for supply of the Product in the Territory or otherwise established logistics for the distribution of the Product in the Territory. S2 is not in material breach of the Patheon Agreement or the Supplemental Patheon Agreements and has not submitted to Patheon any notice (written or oral) to the effect that Patheon is in breach of the Patheon Agreement or the Supplemental Patheon Agreements. S2 has not received from Patheon any notice (written or oral) to the effect that S2 is in breach of the Patheon Agreement or the Supplemental Patheon Agreements. Each of the Patheon Agreement and the Supplemental Patheon Agreements is legal, valid, binding, enforceable and in full force and effect (except as enforcement may be affected by bankruptcy, insolvency or other similar laws and by general principles of equity).
Patheon Agreement. Seller shall assign and Buyer shall assume all rights and obligations under the Patheon Agreement.
Patheon Agreement. Depomed is not in material breach of the Patheon Agreement and has not submitted to Patheon any notice (written or oral) to the effect that Patheon is in breach of the Patheon Agreement. Depomed has not received from Patheon any notice (written or oral) to the effect that Depomed is in breach of the Patheon Agreement. The Patheon Agreement is legal, valid, binding, enforceable and in full force and effect in all material respects.
Patheon Agreement. In November 2013, we entered into a master manufacturing services agreement and product agreement, or, collectively, the Patheon manufacturing agreement, with Patheon who was AstraZeneca’s contract manufacturer of VIMOVO, for the manufacture and supply of VIMOVO. Under the Patheon manufacturing agreement, we agreed to purchase a specified percentage of our VIMOVO requirements for the United States from Patheon or its affiliates. In addition, under the terms of the Patheon manufacturing agreement, we are able to enter into individual product agreements with Patheon for the manufacture of specific medicines in addition to VIMOVO if agreed by us and Patheon.
Patheon Agreement. All of the Seller's rights, and all liabilities, obligations and responsibilities associated therewith under such agreement, but only to the extent such rights, liabilities, obligations and responsibilities relate to the Products, as set forth in the Assignment and Amendment of Manufacturing and Supply Agreement between Buyer, Seller and Patheon Inc.
Patheon Agreement. ▇▇▇▇▇ hereby represents and warrants to Licensee that, as of the Effective Date and with respect to that certain Master Umbrella Development Services Agreement, between Patheon Biologics LLC (“Patheon”) and ▇▇▇▇▇, effective November 12, 2020, as amended and those certain Project Proposals executed thereunder included in the Assigned Product Agreements (the “Assigned Patheon Agreement”) and all activities through Drug Substance (as referred to in the Applicable Patheon Proposals (as defined below)) manufacturing under the Applicable Patheon Proposals, excluding Drug Product (as referred to in the Applicable Patheon Proposals) manufacturing (the “Applicable Patheon Activities”), (i) ▇▇▇▇▇ has received invoices from Patheon totaling $(***) through the latest accounts payable update that occurred on approximately July 20, 2022 (such amount the “Invoiced Patheon Amount”) and (ii) the total amount known to ▇▇▇▇▇ that was, is, or will become due with respect to Applicable Patheon Activities (including corresponding change orders with respect thereto) under the Assigned Patheon Agreement, including the above-referenced $(***), is, as of such update, reasonably estimated by ▇▇▇▇▇ to be $(***) (the “Total Patheon Amount”). To the extent ▇▇▇▇▇ has not paid any portion of the Invoiced Patheon Amount as of the Effective Date, ▇▇▇▇▇ shall, notwithstanding anything to the contrary in this Agreement, remain and be responsible for paying Patheon that amount, and Licensee shall be responsible for paying (and shall, upon assignment of the Assigned Patheon Agreement to Licensee and, consistent with and without limitation of the terms of Schedule 3.4.1, assume the obligation to pay) any portion of the Total Patheon Amount in excess of the Invoiced Patheon Amount (such excess, the “Licensee Patheon Amount”), provided that if invoices for any portion of the Licensee Patheon Amount are received and paid by ▇▇▇▇▇ prior to the assignment of the Assigned Patheon Agreement to Licensee, then Licensee shall reimburse ▇▇▇▇▇ in the amount of any such payment within thirty (30) days of receipt of an invoice therefor from ▇▇▇▇▇. For the sake of clarity, the